Omega-3 Empty Liposomes for Tumor-Site Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing drug-delivery liposomes, particularly those with saturated PC and PEGylated phospholipids, face challenges in drug release at tumor sites, limiting therapeutic efficacy despite accumulation, and have stability and retention issues.
Innovation Solution
A composition comprising a drug-carrying liposome and an empty liposome with omega-3 fatty acid-derived phospholipids, which promotes drug release through inter-membrane action, maintaining stability and extending blood retention time.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If liposomes are made with saturated PC and PEGylated phospholipids to extend blood half-life, then blood retention time is improved, but drug release at tumor sites is hindered due to rigid membrane structure
Solution Approach 1:
The invention divides the liposome system into two functional components: a drug-carrying liposome with saturated PC for stable drug delivery and blood retention, and an empty liposome with unsaturated PC that promotes drug release. This segmentation allows each component to specialize in one function, resolving the contradiction between blood retention and drug release
Solution Approach 2:
The empty liposome acts as an intermediary that facilitates drug release from the drug-carrying liposome. When the two liposomes interact, the unsaturated PC in the empty liposome promotes membrane fluidity and drug release without compromising the stability of the drug-carrying liposome during circulation
2Reliability
If proportion of PEGylated phospholipids is reduced to improve drug release, then drug release is enhanced, but blood half-life extension effects are diminished
Solution Approach 1:
The invention combines two types of liposomes with different phospholipid compositions into a single formulation system. The drug-carrying liposome provides blood retention properties, while the empty liposome provides drug release promotion, achieving both long blood half-life and efficient drug release simultaneously
Solution Approach 2:
The invention changes the phospholipid composition parameter of the empty liposome to contain unsaturated PC, which fundamentally alters the membrane fluidity and drug release characteristics without affecting the stability of the drug-carrying liposome
3Reliability
If unsaturated PC is used as major component to improve membrane fluidity and drug release, then drug release is enhanced, but liposome stability is reduced
Solution Approach 1:
The invention segments the liposome population into stable drug-carrying liposomes and fluid empty liposomes, allowing the unsaturated PC to be present only in the empty liposomes where it promotes drug release, while the drug-carrying liposomes maintain their stability through saturated PC composition
Solution Approach 2:
The invention applies different phospholipid qualities to different functional components: saturated PC in the drug-carrying liposome for stability and blood retention, and unsaturated PC in the empty liposome for drug release promotion, achieving optimal performance in each location
Data Source
AI summary
A composition for delivering a drug includes a drug carrying liposome carrying a drug in a liposome, and an empty liposome which does not carry the drug and includes phospholipid having a head and two fatty acid chains, wherein both of the two fatty acid chains comprises omega-3 fatty acids or their derivatives.